USCF Hellen Diller Family Comprehensive Cancer Center Trials

USCF Hellen Diller Family Comprehensive Cancer Center	Welcome, Profile Billing Logout

USCF Hellen Diller Family Comprehensive Cancer Center

Welcome, Profile Billing Logout

3 Trials

2 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Kelley, Robin K

NCT03439891: Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Active, not recruiting

Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Sorafenib, BAY 43-9006

Robin Kate Kelley, Bayer, Bristol-Myers Squibb

Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8

11/23

11/24

NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing

N/A

TAS-120, Futibatinib

Taiho Oncology, Inc.

Advanced Cholangiocarcinoma

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites